Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Payoneer Global Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Payoneer Global Inc trades at $7.13 (market cap $2.42B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.7× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Payoneer Global Inc for 62 Days on average.
| KYMR | PAYO | |
|---|---|---|
Market Cap | $8.88B | $2.42B |
Volume | 1,028,790 | 1,987,307 |
Sector | Health | Technology |
52-Week High | $127.31 | $7.18 |
52-Week Low | $55.80 | $4.27 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $8.27B | $2.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Payoneer Global (PAYO) trades at $7.15, up 0.42% with mixed technical signals showing a bullish overall trend but bearish moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, while revenue grew 10% excluding interest. Recent developments include the renewal of its Etsy partnership through 2029 and the announcement of a pending acquisition by Nuvei, creating significant investor interest and legal scrutiny.
The outlook remains cautiously optimistic with 60% analyst buy ratings, though earnings volatility and the pending acquisition create uncertainty. Key opportunities include strong B2B growth acceleration (48% YoY) and expanding international presence, while risks involve integration challenges with Nuvei and margin compression as net income margins decline from 16.8% in 2024 to 5.82% projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
